XPH Performance — State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
Data updated: 2026-09-11
XPH returned +18.67% year to date and +64.89% over one year to Jun 2026. Annualised returns are +18.81% over 3 years and +6.46% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $168, against $138 for the category, and to $165 over one year, against $137. Volatility over the past three years was 20.74% a year. In the 12 months to Jun 2026 the fund took in a net $159.8M, and assets reached $428.43M.
XPH Growth of $100
What $100 invested in State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | XPH | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $165 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $168 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $137 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $180 | $182 |
XPH Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +18.67% |
| 1 year | +64.89% |
| 3 years (annualised) | +18.81% |
| 5 years (annualised) | +6.46% |
XPH Annual Returns
Calendar-year total returns of State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +18.67% |
| 2025 | +31.61% |
| 2024 | +5.12% |
| 2023 | +2.86% |
| 2022 | −9.72% |
| 2021 | −10.50% |
| 2020 | +14.38% |
| 2019 (Jul–Dec) | +15.49% |
XPH Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | −1.3% | +3.8% | −5.9% | +6.8% | +1.1% | +14.0% | — | — | — | — | — | — |
| 2025 | +4.9% | −1.2% | −1.3% | −5.9% | −1.6% | 0.0% | +1.8% | +15.0% | +1.4% | +3.6% | +10.1% | +2.7% |
| 2024 | +1.0% | +5.8% | −2.6% | −7.7% | +1.6% | −1.1% | +8.7% | +3.3% | −0.2% | +3.7% | +0.4% | −6.5% |
| 2023 | +6.3% | −5.3% | −0.2% | +2.5% | −6.2% | +4.3% | +6.6% | 0.0% | −8.8% | −9.8% | +3.2% | +12.9% |
| 2022 | −5.6% | −0.5% | +4.8% | −8.7% | +1.7% | +0.4% | +2.0% | −3.1% | −3.1% | +5.4% | +1.6% | −4.2% |
| 2021 | −0.3% | +2.9% | −5.7% | −2.0% | +2.6% | +2.6% | −2.7% | −3.7% | −2.1% | +1.1% | −4.4% | +1.1% |
| 2020 | −0.9% | −9.1% | −12.3% | +16.3% | +2.9% | −0.1% | −1.0% | +3.8% | −1.7% | +1.5% | +8.4% | +8.9% |
| 2019 | — | — | — | — | — | — | −4.5% | −6.6% | +0.7% | +8.6% | +5.7% | +12.0% |
XPH Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 20.74%
- 3-year Sharpe ratio: 0.69 (vs 4.5% risk-free rate)
- Best month: +14.97% (Aug 2025)
- Worst month: −9.85% (Oct 2023)
XPH Fund Flows
Monthly money in and out of State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF, from SEC Form N-PORT.
- 12-month net flow: $159.8M
- 12-month gross sales (incl. reinvestments): $365.5M
- Sales ÷ redemptions: 1.78×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $51.1M | $24.0M | $27.0M |
| May 2026 | $5.9M | $11.3M | −$5.4M |
| Apr 2026 | $25.3M | $0 | $25.3M |
| Mar 2026 | $21.6M | $21.6M | −$31K |
| Feb 2026 | $33.9M | $5.7M | $28.2M |
| Jan 2026 | $83.8M | $22.3M | $61.6M |
| Dec 2025 | $66.1M | $50.7M | $15.5M |
| Nov 2025 | $17.9M | $12.7M | $5.2M |
| Oct 2025 | $26.6M | $24.1M | $2.5M |
| Sep 2025 | $0 | $14.3M | −$14.3M |
| Aug 2025 | $18.5M | $2.1M | $16.4M |
| Jul 2025 | $14.7M | $16.8M | −$2.1M |
XPH Assets Under Management
Net assets of State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $428.43M |
| 2026-03-31 | $307.87M |
| 2025-12-31 | $229.98M |
| 2025-09-30 | $175.18M |
| 2025-06-30 | $147.96M |
| 2025-03-31 | $162.33M |
| 2024-12-31 | $159.27M |
| 2024-09-30 | $186.55M |
| 2024-06-30 | $195.15M |
| 2024-03-31 | $219.96M |
| 2023-12-31 | $222.58M |
| 2023-09-30 | $196.87M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.